Executive Change

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   February 7, 2020 Date of Report (Date of earliest event reported)   ABBOTT LABORATORIES (Exact name of registrant as specified in charter)   Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)   100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class   Trading  Symbol(s)   Name of Each Exchange on Which Registered Common Shares, Without Par Value   ABT   New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On February 7, 2020, Philip P. Boudreau, 47, was appointed Vice President, Finance and Controller, effective March 1, 2020. Mr. Boudreau has served as Abbott’s Divisional Vice President, Controller, Medical Devices since 2017 and served as Divisional Vice President, Controller and Commercial Support, Point of Care from 2012 to 2017. He joined Abbott in 1997.   Mr. Boudreau will receive compensation pursuant to certain plans provided by Abbott, including a base salary, annual incentive, long-term incentive, and other benefits typically available to other similarly situated executive officers.         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     ABBOTT LABORATORIES     February 11, 2020 By:  /s/ Brian B. Yoor     Brian B. Yoor     Executive Vice President, Finance and Chief Financial Officer